|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Pharmacogenomic Testing Markets |
|
|
|
|
€ 2 800,00 |
Editeur
: |
TriMark |
Langue
: |
Anglais |
Date de publication : |
Juin 2006 |
Taille du document : |
162 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
03-026: The Market for Tissue Microarrays
134 pages | Juillet 2003 |
This report provides vital information on end-users’ scientific objectives, instrumentation for production and analysis of TMAs, outsourcing practices and preferred TMA suppliers |
640,00 €
|
| |
| |
Human Cloning: Economics and Ethics
36 pages | Mars 2003 |
Human cloning has moved from science-fiction novels, to science laboratories.
Pro-human cloning companies are racing to create the first cloned child, or make a breakthrough in stem cell research, |
850,00 €
|
| |
| |
Chinese Markets for Biotechnology
153 pages | Janvier 2002 |
China's demand for biotechnology has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic t |
2 835,00 €
|
| |
| |
03-018: Market Opportunities in Cytokine & Growth Factor Research
170 pages | Mai 2003 |
This report identifies preferred quantification and activity assays, new research trends and the most popular suppliers of antibodies, recombinant proteins and DNA microarrays |
800,00 €
|
| |
| |
Target and Lead Validation
160 pages | Décembre 2000 |
The advent of brute force approaches to lead generation has highlighted a key bottleneck in drug development.
The issue is not how many new compounds can one make per day, but rather how many c |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Bioinformatics
150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data.
Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
Revolutionise Drug Discovery through Genomics & Proteomics Study
10 pages | Novembre 2002 |
Genomics and Proteomics are complementary technologies of biological research.
The potential of these technologies for biomedical revolution will be realized by integrating them into the drug disc |
200,00 €
|
| |
| |
Chinese Markets for Biotechnology
153 pages | Janvier 2002 |
China's demand for biotechnology has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic t |
3 500,00 €
|
| |
| |
04-001: Evaluating Online Advertising Opportunities @ Life Science Portals
176 pages | Février 2004 |
This report will help life science executives decide where to spend their advertising budget using the same criteria as their scientific customers, rather than assessing the value of a portal on the b |
1 120,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pharmacogenomic Testing Markets |
|
|
The purpose of this report is to describe the specific market segment of the in vitro diagnostics (IVD) market called pharmacogenomic testing. Pharmacogenomics--the science of individualizing drug therapy based upon the genetic makeup of individual patients--offers an unusual opportunity for future market growth. Applying pharmacogenomics would allow doctors to treat specific segments of the population based on their particular responses to a drug. The knowledge of the likely effectiveness of a drug in a patient makes the drug more reliable, and fewer drugs would have to be taken off the market due to adverse reactions in some of the patients to whom they were administered. This study is arranged to provide an overview of pharmacogenomic testing market segments.
|
|
Table of content available on demand
|
|
|
PPLSEN
|
|
|
|
|
